Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Asymptomatic Gaucher disease implications for large-scale screening.

J Azuri1, D Elstein, A Lahad

  • 1Gaucher Clinic, Shaare-Zedek Medical Center, Jerusalem, Israel.

Genetic Testing
|August 28, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Opportunities and challenges in delivering remote primary care during the Coronavirus outbreak.

BMC primary care·2022
Same author

The diagnostic value of 14-3-3η protein levels in patients with rheumatoid arthritis.

Best practice & research. Clinical rheumatology·2019
Same author

Prodromal substantia nigra sonography undermines suggested association between substrate accumulation and the risk for GBA-related Parkinson's disease.

European journal of neurology·2019
Same author

Altered T cell receptor beta repertoire patterns in pediatric ulcerative colitis.

Clinical and experimental immunology·2018
Same author

Impact of patients' access to medical records in occupational medicine.

Occupational medicine (Oxford, England)·2018
Same author

Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease.

Blood cells, molecules & diseases·2017
Same journal

A novel frameshift mutation in FRMD7 causing X-linked idiopathic congenital nystagmus.

Genetic testing·2008
Same journal

Quantitative fluorescent-PCR detection of sex chromosome aneuploidies and AZF deletions/duplications.

Genetic testing·2008
Same journal

Molecular prenatal diagnosis of muscular dystrophies in Tunisia and postnatal follow-up role.

Genetic testing·2008
Same journal

The polymorphisms on Igkappa gene are related to susceptibility of breast cancer and gastric cancer.

Genetic testing·2008
Same journal

Carrier frequencies of mutations/polymorphisms in the connexin 26 gene (GJB2) in the Moroccan population.

Genetic testing·2008
Same journal

Prevalence of prothrombotic polymorphisms in Greece.

Genetic testing·2008
See all related articles

Large-scale screening for Gaucher disease in Ashkenazi Jews is not recommended. Asymptomatic or mild Gaucher patients show no significant health changes, negating the need for frequent monitoring or prophylactic treatment.

Area of Science:

  • Genetics
  • Biochemistry
  • Medical Screening

Background:

  • Gaucher disease is the most common genetic disorder in Ashkenazi Jews, with seven mutations accounting for over 96% of disease alleles.
  • Significant phenotypic heterogeneity exists, with many mild or asymptomatic cases potentially undiagnosed.
  • Current diagnosis numbers in Israel are far below predicted frequencies, suggesting a large pool of undiagnosed individuals.

Purpose of the Study:

  • To assess the long-term implications of identifying asymptomatic or very mild Gaucher disease patients.
  • To evaluate the need for frequent monitoring and prophylactic enzyme therapy in this patient group.
  • To determine the rationale for large-scale screening programs in the Ashkenazi population.

Main Methods:

  • A cohort of 68 asymptomatic/very mild Gaucher disease patients was followed for an average of 2.6 years.

Related Experiment Videos

  • Objective disease severity markers were monitored.
  • Subjective patient reports on general health status and quality of life were collected.

    • Main Results:

    • No medically significant changes in disease severity were observed during the follow-up period.
    • Patients reported general health status comparable to normal subjects.
    • Quality of life remained stable, with no significant changes noted during follow-up.

    Conclusions:

    • Asymptomatic and mild Gaucher disease patients do not necessitate frequent medical monitoring.
    • There is no justification for prophylactic enzyme therapy in this cohort.
    • Large-scale screening for Gaucher disease in the Ashkenazi population is not supported due to lack of clinical benefit and potential for stigmatization.